A synergistic combination of enrofloxacin and colistin sulfate, the active substances of Enronit, enhance each other’s effects, thus providing a wide range of antimicrobial activity against Gram-positive and Gram-negative microbes. The mechanism of action of enrofloxacin is as follows: enrofloxacin inhibits the activity of gyrase (an enzyme that affects the replication of DNA spiral in the nucleus of the bacterial cell), which allows it to disrupt the protein synthesis and suppress the growth and development of Gram-positive and Gram-negative bacteria including Escherichia coli, Haemophilus spp., Pasteurella spp., Salmonella spp., Staphylococcus spp., Streptococcus spp., Clostridium perfringens, Bordetella spp., Campylobacter spp., Corynebacterium pyogenes, Pseudomonas aeruginosa. and Mycoplasma spp. Colistin sulfate impairs the permeability of the bacterial cell walls by connecting to lypoproteins that leads to a change in the intracellular metabolism and causes death of Gram-negative bacteria including Escherichia coli, Pseudomonas aeruginosa, Klebsiella spp, Salmonella spp. and Proteus spp.
After injection, Enronit is quickly resorbed from the injection site and distributed among the organs and tissues of the animal. Concentration of enrofloxacin in blood serum reaches its peak value after 1-2 hours, while concentration of colistin sulfate in blood serum reaches its peak value after 1 hour. Enrofloxacin and colistin sulfate are eliminated unchanged mostly with feces and partially with urine.